AIX 9.01 ▲0.33% ALU 0.88 ▼-2.22% DN1 99.70 ▼-0.09% EMUCA 0.89 KIT 1.90 ▲0.00% KKC 2.11 ▲0.00% LF1 1.92 ▲0.79% MBG 0.14 ▲0.00% MRE 1.88 ▼-0.53% PCI 1.09 ▼-0.91% PCX 1.99 ▼-0.75% RF1 3.52 ▼-0.28% SET 2.14 ▼-0.47% BST 0.30 ▲3.45% CTS 0.56 ▲1.82% EFR 0.00 ▲0.00% FDC 3.33 ▼-1.19% KOA 3.10 ▲1.64% AIX 9.01 ▲0.33% ALU 0.88 ▼-2.22% DN1 99.70 ▼-0.09% EMUCA 0.89 KIT 1.90 ▲0.00% KKC 2.11 ▲0.00% LF1 1.92 ▲0.79% MBG 0.14 ▲0.00% MRE 1.88 ▼-0.53% PCI 1.09 ▼-0.91% PCX 1.99 ▼-0.75% RF1 3.52 ▼-0.28% SET 2.14 ▼-0.47% BST 0.30 ▲3.45% CTS 0.56 ▲1.82% EFR 0.00 ▲0.00% FDC 3.33 ▼-1.19% KOA 3.10 ▲1.64%

AVE Avecho Biotechnology Limited

Healthcare · Biotechnology · website
$0.02
52wk 0.00 – 0.03
Overall
Value
Growth
Health
Quality
Momentum
Dividend
Price
About Avecho Biotechnology Limited

Avecho Biotechnology Limited, a biotechnology company, develops and commercializes human and animal health products using its proprietary drug delivery system, tocopherol phosphate mixture (TPM) in Australia, Switzerland, France, and India. It operates through Production and Human Health segments. The company manufactures and sells TPM and Vital ET products for use in drug delivery and cosmetic formulations. Its human health portfolio covers delivery of pharmaceutical products through gels, injectables, and patches. In addition, the company develops pharmaceutical products; oral, topical, and edible pharmaceutical cannabinoid products, including a cannabidiol TPM soft-gel capsule in Phase III clinical trial for the treatment of insomnia; and non-antibiotic feed additive products to enhance feed efficiency and the health of livestock animals. The company was formerly known as Phosphagenics Limited and changed its name to Avecho Biotechnology Limited in May 2019. Avecho Biotechnology Limited was incorporated in 1992 and is based in Clayton, Australia.

Fundamental trends
Financial statements
Loading…
Key metrics
Market cap
$73.41M
P/E (trailing)
P/E (forward)
EPS (trailing)
0.00
Dividend yield
Payout ratio
0.0%
Beta
1.11
EV / EBITDA
-17.06
Price / Book
ROE
-182.9%
Operating margin
-198.9%
Net margin
0.0%
Total cash
$4.66M
Total debt
$14,473
Current ratio
9.95
Debt / Equity
0.01
Free cash flow
$-2.14M
Avg volume
14.20M
Latest annual results (FY ending 31 Dec 2025)
  • Revenue$1.25M
  • Gross profit$895.69K
  • Operating income-$6.00M
  • Net income-$4.42M
  • Diluted EPS-0.00
  • Free cash flow$1.10M
  • Net debt-$4.65M
Sector peers (Healthcare)
TickerMkt cap P/EScore
CSL $59.53B 14.0
RMD $43.89B 20.4
SIG $34.28B 59.4
FPH $20.25B 52.2
PME $17.21B 73.5
SHL $10.79B 19.7
RHC $10.13B 34.8
COH $7.90B 22.9